Document Detail


T-cell recognition of ovarian cancer.
MedLine Citation:
PMID:  8342128     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The existence of a tumor-specific T-cell immune response to human malignant melanoma has been well documented. In contrast, the existence of tumor-specific cytotoxic T lymphocyte to ovarian cancer remains controversial despite the abundant lymphocytic infiltrates in the malignant ascites and solid tumor of these patients. METHODS: Tumor-associated lymphocytes (TAL) from the malignant ascites and tumor-infiltrating lymphocytes (TIL) from the solid tumors were isolated from six untreated patients with ovarian cancer. TAL and TIL were grown with initial anti-cluster of differentiation of T cells (CD3), low-dose interleukin-2, and tumor stimulation. T-cell lines were analyzed in functional studies. RESULTS: At 5 weeks, TAL and TIL from five of six patients were > 50% CD8+, and one of six was > 70% CD4+. In all five pairs of CD8 positive cultures, both TAL and TIL exhibited high levels of tumor-specific cytotoxicity for ascite and solid tumor, respectively. T-cell recognition of tumor was mediated through the T-cell receptor-CD3 complex and was human leukocyte antigen class I restricted. TAL and TIL lysed autologous ascitic tumor equally well; however, TAL-mediated tumoricidal activity against autologous solid tumor was consistently and significantly poorer than TIL-mediated killing. CONCLUSIONS: Tumor-specific cytotoxic T lymphocytes can be expanded from both TAL and TIL. However, TAL do not kill solid tumor as efficiently as TIL. This suggests the requirement of TIL, or a combination of TIL and TAL, for effective immunotherapy.
Authors:
G E Peoples; D D Schoof; J V Andrews; P S Goedegebuure; T J Eberlein
Related Documents :
20686958 - Characterization of regulatory t cells in tumor suppressive microenvironments.
19696208 - Blocking pd-1 in cancer immunotherapy.
12077238 - Synergistic antitumor effect of bispecific cd19 x cd3 and cd19 x cd16 diabodies in a pr...
8621268 - Immunophenotype analysis of dendritic cells and lymphocytes associated with cutaneous m...
25389328 - Her2 heterogeneity affects trastuzumab responses and survival in patients with her2-pos...
11696818 - Distribution of dt-diaphorase and reduced nicotinamide adenine dinucleotide phosphate: ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Surgery     Volume:  114     ISSN:  0039-6060     ISO Abbreviation:  Surgery     Publication Date:  1993 Aug 
Date Detail:
Created Date:  1993-08-31     Completed Date:  1993-08-31     Revised Date:  2010-03-24    
Medline Journal Info:
Nlm Unique ID:  0417347     Medline TA:  Surgery     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  227-34     Citation Subset:  AIM; IM    
Affiliation:
Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass. 02115.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antibodies, Monoclonal / immunology
Cytotoxicity, Immunologic
Female
Humans
Lymphocytes, Tumor-Infiltrating / immunology
Middle Aged
Ovarian Neoplasms / immunology*
T-Lymphocytes / immunology*
T-Lymphocytes, Cytotoxic / immunology
Tumor Cells, Cultured
Grant Support
ID/Acronym/Agency:
CA 09535/CA/NCI NIH HHS; R01 CA45484/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Composite kidney-islet transplantation prevents recurrent autoimmune beta-cell destruction.
Next Document:  Soluble factors modulate changes in collagen gene expression in abdominal aortic aneurysms.